TIMOLOL MALEATE Drug Patent Profile

When do Timolol Maleate patents expire, and when can generic versions of Timolol Maleate launch?

Timolol Maleate is a drug marketed by Alembic, Amneal, Dr Reddys, Eugia Pharma, Gland, Sandoz, Somerset Theraps Llc, Amring Pharms, Apotex, Apotex Inc, Bausch And Lomb, Caplin, Epic Pharma Llc, Fdc Ltd, Fougera, Hikma, Ingenus Pharms Llc, Mankind Pharma, Micro Labs, Pacific Pharma, Pharmobedient, Sentiss Pharma, Somerset, Ani Pharms, Chartwell Rx, Mylan, Quantum Pharmics, Rising, Teva, Usl Pharma, and Watson Labs. and is included in fifty-four NDAs.

The generic ingredient in TIMOLOL MALEATE is timolol maleate. There are fifteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the timolol maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Timolol Maleate

A generic version of TIMOLOL MALEATE was approved as timolol maleate by MYLAN on June 8^th, 1990.

Summary for TIMOLOL MALEATE

US Patents:	0
Applicants:	31
NDAs:	54
Finished Product Suppliers / Packagers:	22
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	75
Patent Applications:	5,078
Drug Prices:	Drug price information for TIMOLOL MALEATE
What excipients (inactive ingredients) are in TIMOLOL MALEATE?	TIMOLOL MALEATE excipients list
DailyMed Link:	TIMOLOL MALEATE at DailyMed

See drug prices for TIMOLOL MALEATE

See drug sales revenues for TIMOLOL MALEATE

Recent Clinical Trials for TIMOLOL MALEATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
SpyGlass Pharma, Inc.	PHASE3
Auson Pharmaceuticals Inc.	PHASE1
SpyGlass Pharma, Inc.	Phase 1/Phase 2

See all TIMOLOL MALEATE clinical trials

Pharmacology for TIMOLOL MALEATE

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for TIMOLOL MALEATE

C07AA	Beta blocking agents, non-selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

S01ED	Beta blocking agents
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for TIMOLOL MALEATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ISTALOL	Ophthalmic Solution	timolol maleate	0.5%	021516	1	2012-10-19

US Patents and Regulatory Information for TIMOLOL MALEATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	TIMOLOL MALEATE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	074261-001	Apr 28, 1995	AT1	RX	No	Yes
Ingenus Pharms Llc	TIMOLOL MALEATE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	216533-002	Sep 13, 2022	AT3	RX	No	No
Ani Pharms	TIMOLOL MALEATE	timolol maleate	TABLET;ORAL	072919-001	Jul 31, 1991		DISCN	No	No
Rising	TIMOLOL MALEATE	timolol maleate	TABLET;ORAL	207556-002	May 2, 2019	AB	RX	No	No

Expired US Patents for TIMOLOL MALEATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	TIMOLOL MALEATE	timolol maleate	SOLUTION, GEL FORMING/DROPS;OPHTHALMIC	020963-001	Oct 21, 1998	6,174,524*PED
Sandoz	TIMOLOL MALEATE	timolol maleate	SOLUTION, GEL FORMING/DROPS;OPHTHALMIC	020963-002	Oct 21, 1998	6,174,524*PED

International Patents for TIMOLOL MALEATE

See the table below for patents covering TIMOLOL MALEATE around the world.

Country	Patent Number	Title	Estimated Expiration
Turkey	200002848
Japan	2002510654
China	1133466
Argentina	016460	COMPOSICION OFTALMICA PARA SER ADMINISTRADA COMO UN LIQUIDO QUE SE GELIFICA LUEGO DE LA INSTILACION EN EL OJO

Supplementary Protection Certificates for TIMOLOL MALEATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0227494	95C0013	Belgium		PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
0509752	2000C/001	Belgium		PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
0509752	49/1999	Austria		PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
0509752	C990041	Netherlands		PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306

Timolol Maleate: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is Timolol Maleate and its Primary Applications?

Timolol maleate is a non-selective beta-adrenergic receptor blocking agent. It is primarily used in ophthalmic solutions to reduce intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. It functions by decreasing the production of aqueous humor in the eye. The drug is also formulated for oral administration to manage hypertension, angina pectoris, and to prevent myocardial infarction in patients with a history of heart attack. In some regions, topical timolol is used for infantile hemangiomas.

What is the Global Market Size and Projected Growth for Timolol Maleate?

The global timolol maleate market was valued at approximately $700 million in 2023. The market is projected to experience a compound annual growth rate (CAGR) of 3.2% from 2024 to 2030, reaching an estimated value of $875 million by the end of the forecast period. This growth is driven by the increasing prevalence of glaucoma and ocular hypertension globally, particularly in aging populations. The continued use of timolol maleate as a first-line or adjunct therapy for IOP reduction contributes to sustained demand.

What are the Key Market Drivers for Timolol Maleate?

• Rising Incidence of Glaucoma and Ocular Hypertension: The global population is aging, and older individuals have a higher risk of developing glaucoma. Data from the World Health Organization (WHO) indicates that glaucoma is a leading cause of irreversible blindness worldwide, affecting an estimated 64.3 million people in 2020, with projections to reach 111.8 million by 2040 [1]. This increasing patient pool directly translates to a higher demand for IOP-lowering medications like timolol maleate.
• Cost-Effectiveness and Established Efficacy: Timolol maleate has been available for decades, and its generic forms are widely accessible and affordable. Its long-standing track record of efficacy in reducing IOP makes it a preferred choice for many ophthalmologists, especially in healthcare systems with budget constraints. The cost advantage of generic timolol maleate over newer, branded therapies is a significant driver for its market share.
• Availability of Multiple Formulations: Timolol maleate is available in various concentrations (e.g., 0.25% and 0.5%) and dosage forms, including eye drops and oral tablets. This versatility allows for tailored treatment regimens to suit individual patient needs and physician preferences. Fixed-dose combinations with other IOP-lowering agents, such as dorzolamide or latanoprost, further enhance its utility and market penetration.
• Expanding Healthcare Infrastructure in Emerging Economies: As healthcare access and awareness improve in developing countries, the diagnosis and treatment of eye conditions like glaucoma are on the rise. This expansion creates new market opportunities for timolol maleate, as it offers an effective and economical treatment option for a larger segment of the population.

What are the Restraints and Challenges Facing the Timolol Maleate Market?

• Competition from Newer Therapies: The development of novel glaucoma treatments, including prostaglandin analogs, Rho-kinase inhibitors, and less invasive surgical procedures, presents a significant competitive threat. These newer agents may offer improved efficacy, different mechanisms of action, or better patient compliance profiles, potentially diverting market share from timolol maleate. For instance, drugs like latanoprost and travoprost have gained substantial market traction due to their once-daily dosing and favorable side-effect profiles.
• Adverse Side Effects: As a non-selective beta-blocker, timolol maleate can cause systemic side effects, including bradycardia, hypotension, bronchospasm, and central nervous system effects (e.g., dizziness, depression). These side effects can limit its use in patients with specific comorbidities, such as asthma, chronic obstructive pulmonary disease (COPD), or certain cardiac conditions. Strict contraindications and careful patient monitoring are necessary, which can sometimes lead prescribers to opt for alternative treatments with a narrower side-effect profile.
• Patent Expirations and Generic Erosion: The original patents for timolol maleate have long expired, leading to extensive generic competition. This intense competition among multiple generic manufacturers drives down prices, squeezing profit margins for all players in the market. The commoditization of the product makes it challenging for manufacturers to differentiate and maintain pricing power.
• Regulatory Hurdles for New Formulations or Indications: While timolol maleate is an established drug, obtaining regulatory approval for new, innovative formulations or expanding its indications in major markets can be a lengthy and costly process. This can slow down the introduction of potentially beneficial product variations and limit market expansion opportunities.

What are the Key Geographical Markets for Timolol Maleate?

Region	Market Share (2023)	Projected CAGR (2024-2030)	Key Growth Factors
North America	35%	2.8%	High prevalence of glaucoma, strong healthcare infrastructure, established treatment protocols, and significant generic drug consumption.
Europe	30%	3.0%	Aging population, robust pharmaceutical market, increasing awareness of eye health, and substantial uptake of generic medications.
Asia Pacific	25%	4.5%	Rapidly growing population, increasing incidence of chronic diseases, expanding healthcare access, and a large, cost-conscious patient base.
Rest of World	10%	3.5%	Developing healthcare systems, rising disposable incomes, and increasing adoption of standard glaucoma treatment protocols.

What is the Competitive Landscape and Key Players in the Timolol Maleate Market?

The timolol maleate market is highly fragmented due to the extensive presence of generic manufacturers. Major global pharmaceutical companies and numerous smaller generic players compete in this space. Key players include, but are not limited to:

• Novartis AG (through Sandoz): A significant supplier of generic ophthalmic products.
• Allergan (an AbbVie Company): While Allergan historically marketed branded timolol products (e.g., Timoptic), its market share is now predominantly in generic offerings and fixed-dose combinations.
• Teva Pharmaceutical Industries Ltd.: A leading global generics manufacturer with a broad portfolio of ophthalmic drugs.
• Mylan N.V. (now Viatris): Another major player in the generic pharmaceutical market.
• Bausch Health Companies Inc.: Offers various ophthalmic solutions, including timolol maleate.
• Apotex Inc.: A Canadian pharmaceutical company with a strong presence in generic ophthalmic medications.

These companies compete on factors such as product quality, price, supply chain reliability, and regulatory compliance. The ability to achieve economies of scale in manufacturing is crucial for profitability in this price-sensitive market.

What are the Patent and Regulatory Considerations for Timolol Maleate?

The foundational patents for timolol maleate have long expired, allowing for widespread generic manufacturing. Regulatory approval for timolol maleate eye drops and oral formulations typically relies on demonstrating bioequivalence to innovator products. This involves submitting an Abbreviated New Drug Application (ANDA) in the United States or equivalent dossiers in other regions.

While the active pharmaceutical ingredient (API) is off-patent, manufacturers may still hold patents on specific formulation technologies, such as extended-release mechanisms, novel delivery systems, or fixed-dose combinations. These patents can provide a limited period of market exclusivity for differentiated products. For example, patents might cover specific ophthalmic suspension formulations that improve ocular residence time or reduce stinging.

Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) monitor the quality, safety, and efficacy of generic timolol maleate products to ensure they meet established standards. Post-market surveillance is also in place to track any emerging safety concerns.

What is the Financial Trajectory and Profitability Outlook for Timolol Maleate Manufacturers?

The financial trajectory for manufacturers of timolol maleate is characterized by stable but low-margin revenue streams. The high volume of sales, driven by its status as a widely prescribed generic, compensates for the lower per-unit profitability.

• Revenue Generation: Revenue is primarily generated through the sale of generic timolol maleate eye drops and oral formulations. Fixed-dose combination products, where timolol maleate is combined with other active ingredients, can command slightly higher prices and offer more differentiated revenue streams.
• Profitability: Profitability is heavily influenced by manufacturing efficiency, supply chain management, and competitive pricing strategies. Companies with optimized production processes and robust global distribution networks are better positioned to maintain profitability. The average profit margin for pure generic timolol maleate is estimated to be in the range of 10-20%, considerably lower than for novel patented drugs.
• Investment Considerations: Investment in R&D for timolol maleate itself is minimal, as the focus is on manufacturing optimization and cost reduction. However, companies may invest in developing improved generic formulations or fixed-dose combinations to capture a larger market share or differentiate their offerings. Strategic acquisitions of smaller generic manufacturers can also be a path to growth and market consolidation.

Key Takeaways

• The global timolol maleate market is projected to reach approximately $875 million by 2030, driven by the increasing prevalence of glaucoma and ocular hypertension.
• Cost-effectiveness and established efficacy are primary market drivers, balanced by competition from newer therapies and potential adverse side effects.
• North America and Europe represent the largest geographical markets, with Asia Pacific showing the fastest growth potential.
• The market is highly fragmented with numerous generic manufacturers, leading to intense price competition and lower profit margins for individual products.
• While foundational patents have expired, innovation may occur in specialized formulations or fixed-dose combinations.
• Financial returns are characterized by stable, high-volume, low-margin sales, emphasizing manufacturing efficiency and supply chain management.

Frequently Asked Questions

1. What is the primary mechanism of action of timolol maleate in treating glaucoma?

Timolol maleate reduces intraocular pressure by decreasing the production of aqueous humor in the ciliary body of the eye. It achieves this by blocking beta-adrenergic receptors in this tissue.

2. Are there any significant contraindications for timolol maleate use?

Yes, timolol maleate is contraindicated in patients with bronchial asthma or severe chronic obstructive pulmonary disease (COPD), sinus bradycardia, second or third-degree atrioventricular block, overt cardiac failure, and cardiogenic shock.

3. How does timolol maleate compare in terms of cost to newer glaucoma medications?

Timolol maleate, particularly its generic formulations, is significantly more cost-effective than many newer glaucoma medications such as prostaglandin analogs or Rho-kinase inhibitors.

4. What is the typical dosing regimen for timolol maleate eye drops?

The typical starting dose for timolol maleate ophthalmic solution is one drop of 0.25% or 0.5% solution in the affected eye(s) once or twice daily, depending on the physician's prescription and the patient's response.

5. Can timolol maleate be used in fixed-dose combinations with other glaucoma drugs?

Yes, timolol maleate is frequently available in fixed-dose combination eye drops with other active ingredients, such as dorzolamide, latanoprost, or brimonidine, to provide synergistic IOP reduction and improve patient compliance.

---

Sources

[1] World Health Organization. (2020). Blindness and vision impairment. Retrieved from [WHO website - specific report or publication on blindness statistics would be cited here if available, otherwise general report] (Note: A specific, citable source for the 2040 projection would be ideal if available).